European journal of obstetrics, gynecology, and reproductive biology
-
Eur. J. Obstet. Gynecol. Reprod. Biol. · Aug 2006
Randomized Controlled Trial Multicenter StudyAntihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil.
Drug treatment is imperative for pregnant women with pregnancy-induced hypertension (PIH) and pre-eclampsia. For more than 40 years, dihydralazine has been the drug of choice for this indication. Another particularly effective and better tolerable antihypertensive is urapidil. Yet only a few studies on limited patient collectives have been published on the clinical experience with urapidil in PIH. ⋯ Urapidil proved to be equally effective as dihydralazine in lowering BP in patients with pre-eclampsia, but showed a better controllability and tolerability. Urapidil can hence be recommended as a promising alternative for patients with PIH.
-
Eur. J. Obstet. Gynecol. Reprod. Biol. · Aug 2006
Randomized Controlled Trial Multicenter StudyCost effectiveness of a screen-and-treat program for asymptomatic vaginal infections in pregnancy: towards a significant reduction in the costs of prematurity.
The purpose of this investigation was to determine the cost-saving potential of a simple screen-and-treat program for vaginal infection, which has previously been shown to lead to a reduction of 50% in the rate of preterm births. ⋯ A simple preterm prevention program, consisting of screening and antimicrobial treatment and follow-up of women with asymptomatic vaginal infection, leads not only to a significant reduction in the rate of preterm births but also to substantial savings in the direct costs associated with prematurity.
-
Eur. J. Obstet. Gynecol. Reprod. Biol. · Feb 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialClinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial.
To explore the efficacy and safety of tranexamic acid at caesarian section (CS). ⋯ Tranexamic acid statistically reduces the extent of bleeding from placental delivery to 2 h postpartum and its use was not associated with any side effects or complications. Thus, tranexamic acid can be used safely and effectively to reduce bleeding resulting from CS.
-
Eur. J. Obstet. Gynecol. Reprod. Biol. · Aug 2003
Multicenter StudyPerinatal outcome of fetuses with a birth weight greater than 4500 g: an analysis of 3356 cases.
To assess the perinatal outcome in a series of macrosomic fetuses according to the intended mode of delivery, and to estimate the individual risk of shoulder dystocia and brachial plexus injury upon information available either prior the onset of labor or at delivery. ⋯ Since some of these risk factors are known prior to delivery, each woman whose fetus is suspected to weight more than 4500 g should be counseled on her individual risk of severe perinatal morbidity before a decision on the mode of delivery is taken.
-
Eur. J. Obstet. Gynecol. Reprod. Biol. · Oct 2001
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialTreatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol.
To compare the efficacy and safety of atosiban and salbutamol in the treatment of preterm labor. ⋯ The oxytocin antagonist atosiban was found to be better tolerated by both mother and fetus than salbutamol, with a comparable neonatal and infant safety profile, and atosiban was as effective as salbutamol in delaying threatened preterm birth. This study supports the clinical use of atosiban in the treatment of preterm labor.